Coverage of Conditions and Treatments (Coverage Decisions)
Dual X-ray absorptiometry (DXA) is the standard technology for measuring bone mineral density and diagnosing osteopenia or osteoporosis
Bone mineral density testing with dual x-ray absorptiometry (DXA) is a covered benefit with conditions.
Conditions of Coverage
Initial Screening:
Asymptomatic women
- Women ≥ 65,
Or - Younger women with equivalent ten year fracture risk to women age 65 as calculated by FRAX* (Fracture Risk Assessment) tool or other validated scoring tool.
Men or women
- Long term exposure to glucocorticoids (i.e. current or past exposure to glucocorticoids for more than 3 months),
- Androgen deprivation,
Or - Other conditions known to be associated with low bone mass.
Repeat Screening:
- T-score** > -1.5, 15 years to next screening test
- T-score -1.5 to -1.99, 5 years to next screening test
- T-score ≤ -2.0, 1 year to next screening test
Or - Use of medication associated with low bone mass or presence of a condition known to be associated with low bone mass.
Monitoring Treatment:
- Once treatment for osteoporosis has begun, serial monitoring is not covered
- Development of a fragility fracture alone is not a covered indication
* FRAX available at: http://www.shef.ac.uk/FRAX/
**T-Score refers to result of a DXA (dual-energy x-ray absorptiometry) scan compared to a reference population.
Background Policy Information
The State Health Technology Clinical Committee (HTCC) reviewed screening & monitoring tests for osteopenia/osteoporosis on November 21, 2014. The committee’s determination, based on a systematic review of the evidence of safety, efficacy and cost-effectiveness, is that the tests are a covered benefit with conditions. Complete information on this HTCC determination is available here: What we're working on | Washington State Health Care Authority.
Implementation of the Decision
A DXA scan may be used only for care of a condition accepted on the claim. All requests require prior authorization.